Wells Fargo analyst David Maris attributes the 5% selloff today in shares of Allergan (AGN) to heightened fears of opioid liability risks in the sector. Maris spoke to Allergan's investor relations team, which noted the company is fully indemnified regarding legacy Actavis generics issues. Further, Allergan has very little exposure to branded opioid sales, as they represent a very small percentage of the company's branded business, Maris tells investors in a research note. He believes the decline in Allergan shares is an overreaction to the negative headlines related to opioid-based litigation facing a number of specialty pharma companies such as Teva (TEVA), Mylan (MYL), and Mallinckrodt (MNK). Maris calls the selloff overdone and recommends buying shares of Allergan. He keeps an Outperform rating on the name with a $188 price target.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."